|1.||Caron, Dania: 7 articles (09/2006 - 04/2002)|
|2.||Merad, Miriam: 4 articles (06/2013 - 03/2002)|
|3.||Agrawal, Devendra K: 4 articles (04/2009 - 04/2004)|
|4.||Guha, Chandan: 3 articles (08/2014 - 01/2006)|
|5.||Deb, Niloy J: 3 articles (08/2014 - 01/2006)|
|6.||Talmadge, James E: 3 articles (04/2007 - 04/2004)|
|7.||Engleman, Edgar G: 3 articles (03/2005 - 03/2002)|
|8.||Fan, Zuoheng: 2 articles (08/2014 - 01/2006)|
|9.||Kawashita, Yujo: 2 articles (08/2014 - 08/2014)|
|10.||Alfieri, Alan: 2 articles (08/2014 - 01/2006)|
07/01/2002 - "Because the origin of tumor cells was not clear and they exhibited a nonlineage-specific phenotype, we hypothesized that such tumors likely originated from hematologic-myeloid precursor cells and were tentatively assigned the designation "agranular CD4+ CD56+ hematodermic neoplasms." In the present study we report 14 cases (seven already reported and seven additional cases) of these tumors, and simultaneously we present now a rare population of cells that we have identified in the peripheral blood of healthy volunteers treated with Flt3 ligand. "
08/01/2014 - "We have demonstrated that the addition of recombinant adenovirus-expressing human Flt3 ligand (Adeno-Flt3L) after radio-inducible suicide gene therapy induced a Th1-biased, immune response and enhanced tumor control in an ectopic model of HCC. "
08/01/2014 - "To prevent liver tumor recurrence and control systemic disease while limiting the potential bystander toxicity of HSV-TK therapy, we proposed to stimulate endogenous dendritic cell (DC) proliferation with systemic adenovirus Flt3 ligand (Adeno-Flt3L) gene therapy, followed by primary tumor radiation therapy combined with a radio-inducible HSV-TK gene therapy. "
08/01/2014 - "1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model."
02/01/2007 - "Flt3 ligand production of in vitro transfected tumor cells and in vivo transfected tumors was measured by enzyme-linked immunosorbent assay. "
|2.||Neoplasm Metastasis (Metastasis)
03/01/2006 - "The combination of the Flt3 ligand and the vaccine also decreased the incidence of metastases and was the most effective treatment. "
03/01/2006 - "Regarding laparotomy, Flt3 ligand (mean, 1.22 metastases), whole cell vaccine (1.12 metastases), and the combination of these two agents (0.1 metastases) were each effective in significantly decreasing the number of surface lung metastases compared with surgery alone (9.88 metastases, P < .05 for all comparisons). "
11/01/2003 - "NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model."
12/10/2003 - "Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy."
03/01/2006 - "Perioperative treatment with either Flt3 ligand or a whole cell tumor vaccine significantly reduced the number of lung metastases after laparotomy. "
|3.||Prostatic Neoplasms (Prostate Cancer)
11/01/2003 - "Thus, these data demonstrate that prostate cancer inhibits DC hematopoietic precursors in vivo in the bone marrow and this effect could be abolished by a systemic administration of growth factor Flt3 ligand."
05/01/2005 - "Flt3 ligand, a growth and differentiation factor for dendritic cells, has shown modest clinical activity in prostate cancer, presumably by eliciting anti-cancer immune responses. "
11/01/2003 - "Notably, Flt3 ligand-based therapy reversed the inhibitory effects of prostate cancer on dendropoiesis in vivo in wild-type and C.B-17 SCID (T and B cell deficient) mice, but not in SCID beige (T, B, and NK cell deficient) animals, suggesting a key role of NK cells in Flt3 ligand-mediated protection of dendropoiesis from tumor-induced inhibition in vivo. "
02/15/2004 - "The purpose of this study was to evaluate the safety, biological activity, and feasibility of repeated doses of the dendritic cell (DC)-stimulating agent Flt3 ligand (FL) in patients with bone scan-negative hormone-refractory prostate cancer. "
05/01/2005 - "The authors now report the identification of prostate-associated proteins immunologically recognized in 13 prostate cancer patients treated with multiple cycles of flt3 ligand. "
12/01/2012 - "Treatment of aged mice with Flt3 ligand (Flt3L) improved the number of DC present in the spleen prior to Lm-OVA infection, and improved, but did not reconstitute, OT-I expansion to Lm-OVA infection. "
03/01/2013 - "The abundance of multipotent progenitor cells (Lin(-)/c-kit(+)/Flt3(+)) in BM declined ∼10-fold during CVB3 infection and, consistent with a deficiency of primitive hematopoietic progenitors, serum levels of the hematopoietic growth factor Flt3 ligand were dramatically elevated. "
10/01/2011 - "In the peripheral T cell compartment, CD8(+) T cell levels were markedly increased in Flt3 ligand-treated mice after infection. "
10/01/2011 - "We examined the effects of Flt3 ligand, a cytokine that induces dendritic cell production, in vivo on the course of infection with Plasmodium berghei ANKA. "
05/25/2010 - "Flt3 ligand (Flt3L) is transiently induced in the serum upon infection or TLR activation. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/30/2011 - "The question now arises as to whether these high levels of FLT3 ligand are actually promoting relapse, and, if so, how we can use this information to adjust our therapeutic approach and improve the cure rate for acute myeloid leukemia with FLT3/ITD."
01/01/2004 - "FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells."
11/15/1996 - "Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax."
03/01/2001 - "In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice."
02/01/2001 - "Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia."
|1.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||DNA (Deoxyribonucleic Acid)
|8.||Serine Proteases (Serine Protease)
|9.||Myeloblastin (Proteinase 3)
|10.||Transcription Factors (Transcription Factor)
|5.||Stem Cell Transplantation